Prokarium: Prokarium Expands R&D Capabilities with London Biofoundry to Deepen Microbial Immunotherapy Pipeline

(marketscreener.com) Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, has entered into an agreement, through Imperial Projects, to work with independent researchers from Imperial College London to develop Prokarium's next-generation therapeutic candidates, engineered to deliver payloads within the tumor...https://www.marketscreener.com/news/latest/Prokarium-Expands-R-D-Capabilities-with-London-Biofoundry-to-Deepen-Microbial-Immunotherapy-Pipeline--37643322/?utm_medium=RSS&utm_content=20220126